Zytorvi
Toripalimab
Vial: 240 mg
Therapeutic Areas
Immuno-oncology
Indications
- Metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)
- Unresectable or metastatic melanoma
Shelf Life
3 years
Launched Year
2024
Available in
India
What is Zytorvi?
Zytorvi, our brand name for Toripalimab, is a monoclonal antibody used in cancer treatment, specifically targeting the PD-1 protein on immune cells. It is approved for treating nasopharyngeal carcinoma, both as a first line treatment in combination with chemotherapy and as a single agent in advanced cases.
Need more information? See our downloadable files.
- Presentation
Storage Conditions
2-8 degrees Celsius (refrigerate), Do not freeze.
Presentation
Vial containing solution for infusion
Route of Administration
Intravenous (IV) (upon prescription only and administered by a healthcare provider)
Indications
How Toripalimab works?
Mechanism of Action
Toripalimab is a humanized monoclonal antibody that targets PD-1, a checkpoint protein on T cells that normally helps keep the body's immune responses in check. By blocking PD-1, Toripalimab enhances the immune system's ability to attack cancer cells. This mechanism involves the inhibition of the PD-1/PD-L1 pathway, which is crucial for the immune evasion of cancer cells.
We Meet Global Standards
- Publication
- 22-06-2016
Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs
- Publication
- 31-03-2017
Long‑term outcome of diffuse large B‑cell lymphoma: Impact of biosimilar rituximab and radiation
- Publication
- 13-01-2017
Safety and Efficacy of an Anti‑CD20 Monoclonal Antibody (Reditux) In Indian Patients with Seropositive Rheumatoid Arthritis
- Publication
- 25-03-2022